IMC Chicago LLC Makes New Investment in GoodRx Holdings, Inc. (NASDAQ:GDRX)

IMC Chicago LLC acquired a new position in shares of GoodRx Holdings, Inc. (NASDAQ:GDRX - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 65,315 shares of the company's stock, valued at approximately $304,000.

Several other large investors have also made changes to their positions in GDRX. AQR Capital Management LLC lifted its position in shares of GoodRx by 181.1% during the 2nd quarter. AQR Capital Management LLC now owns 46,159 shares of the company's stock worth $360,000 after purchasing an additional 29,741 shares during the last quarter. Vontobel Holding Ltd. lifted its position in shares of GoodRx by 78.4% during the 3rd quarter. Vontobel Holding Ltd. now owns 93,750 shares of the company's stock worth $651,000 after purchasing an additional 41,196 shares during the last quarter. nVerses Capital LLC acquired a new position in shares of GoodRx during the 3rd quarter worth about $33,000. Raymond James & Associates lifted its position in shares of GoodRx by 212.6% during the 3rd quarter. Raymond James & Associates now owns 394,006 shares of the company's stock worth $2,734,000 after purchasing an additional 267,951 shares during the last quarter. Finally, CWA Asset Management Group LLC acquired a new position in GoodRx in the 3rd quarter valued at approximately $370,000. Institutional investors and hedge funds own 63.77% of the company's stock.

Wall Street Analysts Forecast Growth

GDRX has been the subject of several recent research reports. Morgan Stanley cut their price target on GoodRx from $7.00 to $6.00 and set an "equal weight" rating for the company in a report on Tuesday, December 17th. Mizuho initiated coverage on GoodRx in a report on Wednesday, December 4th. They issued a "neutral" rating and a $5.00 price target for the company. KeyCorp cut their price target on GoodRx from $7.00 to $6.00 and set an "overweight" rating for the company in a report on Wednesday, January 8th. Citigroup cut their price target on GoodRx from $7.00 to $6.25 and set a "buy" rating for the company in a report on Friday, January 10th. Finally, Barclays cut their price target on GoodRx from $10.00 to $6.00 and set an "overweight" rating for the company in a report on Monday, November 11th. Five equities research analysts have rated the stock with a hold rating, nine have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $8.38.

GoodRx Price Performance

NASDAQ GDRX traded up $0.01 during trading hours on Friday, reaching $5.04. 588,375 shares of the company's stock were exchanged, compared to its average volume of 1,063,297. The stock has a market cap of $1.92 billion, a PE ratio of -168.00, a price-to-earnings-growth ratio of 2.44 and a beta of 1.28. GoodRx Holdings, Inc. has a one year low of $4.09 and a one year high of $9.26. The firm has a fifty day moving average of $4.65 and a 200-day moving average of $5.93. The company has a current ratio of 5.48, a quick ratio of 5.48 and a debt-to-equity ratio of 0.70.

GoodRx Company Profile

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.